Letters, Testimony & Comments

November 6, 2013 The Honorable Robert Menendez 528 Hart Senate Office Building United States Senate Washington, D.C....
November 6 2013
Kenneth I. Moch President and Chief Executive Officer, Chimerix, Inc. On behalf of the Biotechnology Industry Organization Before the...
July 10 2013
Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals On behalf of the Biotechnology Industry...
July 26 2012
Dear Majority Leader Reid and Minority Leader McConnell: On behalf of the Biotechnology Industry Organization (BIO) and its more than 1...
March 16 2012
William D. Waddill, Senior Vice President and Chief Financial Officer OncoMed Pharmaceuticals highlights the importance of capital...
March 6 2012
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of...
December 1 2011
Good morning Chairman Casey, Vice Chairman Brady, Ranking Member DeMint, Ranking Member Hinchey, Members of the Committee, ladies, and...
May 25 2011
Dear Chairman Frelinghuysen and Ranking Member Visclosky: On behalf of the Biotechnology Industry Organization (BIO), I am writing to...
May 17 2011
Hearing Testimony Scott Koenig, M.D., PH.D. Before the House of Representatives Committee on Small Business Good morning Chairman...
April 7 2011
Re: Request for Comments on the Strategy for American Innovation Subject: Innovation Strategy RFI Email: competitiveness@doc.gov Dear...
April 1 2011
SECTION 1. PURPOSE This notice establishes the qualifying therapeutic discovery project program under § 48D of the Internal...
August 3 2010
BIO advocated for the recently enacted new Therapeutic Discovery Project Credit program, which was created as a unique opportunity for...
August 3 2010
A letter to the House Ways & Means Committee by 54 trade organizations and companies supporting the extension of cellulosic biofuel...
June 23 2010
Dear Chairman Inouye and Ranking Member Cochran: As the Senate debates fiscal year 2011 federal funding, the undersigned organizations...
June 1 2010
Access to Early Capital In the United States and globally, commercial development of biotechnology relies on the continuing...
May 27 2010
BIO and 34 companies and trade organizations sent a letter to Chairman Levin and Ranking Member Camp, of the House Ways and Means...
May 17 2010
Dear Ms. Blue, This letter is submitted by the Biotechnology Industry Organization (BIO) in response to the request for public comment...
November 3 2009
Good morning Chairwoman Velázquez, Ranking Member Graves, Members of the Committee, the Staff of the Committee, ladies and...
October 14 2009
Good morning Chairman Wu, Ranking Member Smith, Members of the Committee, ladies and gentleman. I am Jim Greenwood, President and CEO of...
April 23 2009
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with...
April 20 2009
BIO urges that changes to FIN46(R) accurately reflect the underlying economics of collaborations.
November 15 2008
Re: SEC Release No. 34-58572 Dear Chairman Cox: On behalf of its members, the Biotechnology Industry Organization (“BIO...
October 27 2008
Dear Chairman Cox and Director Thomsen: On behalf of its members, the Biotechnology Industry Organization (“BIO”) would...
September 22 2008
The letter, signed by approximately 60 patient groups, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
September 18 2008
BIO addresses concerns to FASB’s Staff Position on accounting for instrument C and conventional convertible debt.
October 27 2007
The Biotechnology Industry Organization (BIO) appreciates this opportunity tp provide the perspective of its members on the Bayh-Dole Act...
August 27 2007
The letter, signed by over 280 biotech executives, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
July 26 2005
To Hector Barreto, Administrator, U.S. Small Business Administration
November 4 2003
To Hector Barreto, Administrator, U.S. Small Business Administration
October 21 2003
Administrator, U.S. Small Business Administration
May 13 2003
BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies....
The 2009 Government-Business Forum on Small Business Capital Formation recommended a permanent exemption for small companies from Section...
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with...
April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
March 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.
September 4 2014
Washington, D.C. (September 4, 2014) – The Biotechnology Industry Organization (BIO) is pleased to announce the winners of the 2014 BIO Investor Forum Buzz of BIO contest, which recognizes highly innovative companies in the biotech sector. Taking place October 7-8, 2014 at the Palace Hotel in San Francisco, California, the 13th Annual BIO Investor Forum will focus on investment opportunities for early stage and established private companies as well as emerging public companies.
August 6 2014
Survey responses will help inform Prescription Drug User Fee Act VI negotiations
May 9 2014
Bill would strengthen, make permanent critical R&D tax credit
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.